Please assess the completion status of the following clinical trial:

Trial Title: COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must be diagnosed with primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia-myelofibrosis (PET-MF) according to the 2008 World Health Organization criteria~* Subjects with myelofibrosis requiring therapy must be classified as high risk OR intermediate risk level 2 according to the prognostic factors defined by the International Working Group~* Subjects with an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, 2 or 3~* Subjects who have not previously received treatment with a Janus kinase (JAK) inhibitor~Exclusion Criteria:~* Subjects with a life expectancy of less than 6 months~* Subjects with inadequate bone marrow reserve as demonstrated by specific clinical laboratory counts~* Subjects with inadequate liver or renal function~* Subjects with clinically significant bacterial, fungal, parasitic or viral infection which require therapy~* Subjects with an active malignancy over the previous 5 years except specific skin cancers.~* Subjects with severe cardiac conditions~* Subjects who have had splenic irradiation within 12 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ruxolitinib (Type: EXPERIMENTAL): Participants received ruxolitinib orally twice a day. The starting dose was determined based on Baseline platelet count. Patients with Baseline platelet count \> 200,000/μL began a dose regimen of 20 mg twice daily. Patients with Baseline platelet count of 100,000/μL to 200,000/μL (inclusive) began a dose regimen of 15 mg twice daily. The dose was adjusted by the Investigator based on efficacy and safety to a maximum of 25 mg twice daily. Patients receiving benefit could continue treatment until the later of marketing approval or when the last randomized patient remaining in the study had completed Week 144 (36 months).
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets matching ruxolitinib were administered orally twice a day at a starting dose based on Baseline platelet count. Doses were titrated using the same guidelines as for active drug. Patients meeting certain protocol requirements detailed below were given the opportunity to cross over to ruxolitinib treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).